黄葵胶囊联合ACEI类药物在特发性膜性肾病患者中的应用

Application of Huangkui capsule combined with ACEI drugs in patients with idiopathic membranous nephropathy

目的探讨黄葵胶囊降低特发性膜性肾病蛋白尿的疗效。方法收集2013年5月至2016年1月病理确诊为膜性肾病,24 h蛋白尿<3.5 g的67例患者随机分为两组,研究组35例,对照组32例。对照组使用单纯血管紧张素转化酶抑制剂(ACEI)类药物治疗,研究组采用黄葵胶囊联合ACEI治疗。比较两组患者蛋白尿的变化情况。结果治疗前,研究组24 h尿蛋白为(3.26±0.37)g,对照组为(3.19±0.29)g,两组比较差异未见统计学意义(P>0.05);治疗后8周,研究组和对照组24 h尿蛋白值分别为(1.31±0.11)、(2.60±0.26)g,前者明显低于后者,差异有统计学意义(P<0.05)。结论采用黄葵胶囊联合ACEI降低特发性膜性肾病患者蛋白尿效果显著,值得在临床上推广使用。

Objective To investigate the effect of Huangkui capsule reducing proteinuria on idiopathic membranous nephropathy.Methods From May 2013 to January 2016, 67 patients with pathological diagnosis of membranous nephropathy, 24 hous proteinuria less than 3.5 g, were randomly divided into the study group（35 cases） and the control group（32 cases）.Patients in the control group were given ACEI therapy alone, and patients in the study group were treated with Huangkui capsule combined with ACEI.The changes of proteinuria were compared between the two groups.Results Before treatment, the 24-hour proteinuria of study group was （3.26±0.37）g, and that of the control group was （3.19±0.29）g, the difference was not significant between the two groups（P〉0.05）;after 8 weeks of treatment, the 24-hour proteinuria of study group was （1.31±0.11）g, which was lower than that of control group[（2.60±0.26）g], the difference was significant（P〈0.05）.Conclusion The effect of Huangkui capsule combined with ACEI on reducing proteinuria in patients with idiopathic membranous nephropathy is significant, it is worthy to be popularized in clinics.